Empagliflozin
- PDF / 169,167 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 15 Downloads / 187 Views
1
S
Death: case report In a disproportionality analysis of 31070 reports submitted to the FDA database of adverse event (AE) reporting system, a patient [age and sex not stated] was described, who died during treatment with empagliflozin for type II diabetes mellitus [dosage, route, duration of treatment to reaction onset and cause of death not stated]. Author comment: "Health care professionals should be cautious about the possibility of encountering serious AEs associated with empagliflozin". "[O]ne death was reported." Sharma V, et al. PDB111 EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE. Value in Health 22 (Suppl. 3): S592-S593 (plus poster) abstr. PDB111, Nov 2019. Available from: URL: http:// 803443902 doi.org/10.1016/j.jval.2019.09.993 [abstract] - India
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
